Reviews
16 June 2025
New papers
Safety and efficacy of left atrial appendage closure in cancer versus non-cancer patients: a systematic review and meta-analysis
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
58
Views
14
Downloads
Authors
There is an ongoing debate regarding the safety and efficacy of left atrial appendage occlusion (LAAO) for atrial fibrillation in patients with cancer. We searched PubMed and Scopus from the database's inception until November 2024 and included studies comparing cancer patients with non-cancer patients undergoing left atrial appendage closure for atrial fibrillation. Our primary outcome was short-term mortality. Secondary outcomes were ischemic stroke, major bleeding, device complications, and pericardial complications. For the dichotomous outcomes, risk ratios (RR) were used, whereas generic inverse variance (GIV) was used to pool the RRs and corresponding 95% confidence interval (95% CI). A random effects model was used to evaluate all the outcomes. Our analysis showed a significantly higher rate of short-term mortality in patients with cancer as compared to non-cancer patients (RR=2.07; 95% CI [1.12 to 3.84]; p=0.02). From secondary outcomes, pericardial complications showed a significantly higher risk in cancer patients (RR: 2.17, 95% CI [1.51, 3.12]; p<0.0001). Meanwhile, other secondary outcomes were found to be insignificant. LAAO in cancer patients was significantly associated with higher short-term mortality and pericardial complications.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–47. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.005119
2. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154–62. DOI: https://doi.org/10.1016/S0140-6736(14)61774-8
3. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 2021;16:217–21. DOI: https://doi.org/10.1177/1747493019897870
4. Migdady I, Russman A, Buletko AB. Atrial fibrillation and ischemic stroke: a clinical review. In: Seminars in Neurology. Thieme Medical Publishers; 2021. p. 348–64. DOI: https://doi.org/10.1055/s-0041-1726332
5. Lutsey PL, Norby FL, Alonso A, et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities study. J Thromb Haemost 2018;16:670–9. DOI: https://doi.org/10.1111/jth.13974
6. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Pol Heart J2016;74:1359-469. DOI: https://doi.org/10.5603/KP.2016.0172
7. Sanna T, Diener HC, Passman RS, Di et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–86. DOI: https://doi.org/10.1056/NEJMoa1313600
8. Dobkin BH. Rehabilitation after stroke. N Engl J Med 2005;352:1677-84. DOI: https://doi.org/10.1056/NEJMcp043511
9. Escobar A, Salem AM, Dickson K, et al. Anticoagulation and bleeding in the cancer patient. Support Care Cance. 2022;30:8547-57. DOI: https://doi.org/10.1007/s00520-022-07136-w
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W-65-94. DOI: https://doi.org/10.7326/0003-4819-151-4-200908180-00136
11. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60. DOI: https://doi.org/10.1136/bmj.327.7414.557
13. Zhang Y, Yang Z, Almani MU, et al. Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer. Cardio-Oncology 2023;9:39. DOI: https://doi.org/10.1186/s40959-023-00192-z
14. Aarnink EW, Ince H, Kische S, et al. Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial. Europace 2024;26:euae188. DOI: https://doi.org/10.1093/europace/euae188
15. Fowler H, Belot A, Ellis L, , et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer 2020;20:1–15. DOI: https://doi.org/10.1186/s12885-019-6472-9
16. Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol 2016;32:852–62. DOI: https://doi.org/10.1016/j.cjca.2015.12.023
17. Bertolini D, Pizzi C, Donal E, Galli E. Cancer and heart failure: dangerous liaisons. J Cardiovasc Dev Dis 2024;11:263. DOI: https://doi.org/10.3390/jcdd11090263
18. Bower JE, Ganz PA, Irwin MR, et al. Acute and chronic effects of adjuvant therapy on inflammatory markers in breast cancer patients. JNCI Cancer Spectr 2022;6:pkac052. DOI: https://doi.org/10.1093/jncics/pkac052
19. Agarwal S, Guha A, Munir MB, et al. Outcomes of patients with cancer undergoing percutaneous left atrial appendage occlusion. J Interv Card Electrophysiol 2023;66:1791-4. DOI: https://doi.org/10.1007/s10840-023-01621-w
20. Hobohm L, von Bardeleben RS, Ostad MA, et al. 5-year experience of in-hospital outcomes after percutaneous left atrial appendage closure in Germany. JACC Cardiovasc Interv 2019;12:1044-52. DOI: https://doi.org/10.1016/j.jcin.2019.04.002
21. Shabtaie SA, Tan NY, Ward RC, et al. Left atrial appendage occlusion in patients with atrial fibrillation and cancer. JACC CardioOncol 2023;5:203-12. DOI: https://doi.org/10.1016/j.jaccao.2022.10.016
22. Tung M, Chen T. LAAO in cardio-oncology: protecting the delicate balance between stroke and bleeding? JACC CardioOncol 2023;5:213-5. DOI: https://doi.org/10.1016/j.jaccao.2023.03.004
23. Isogai T, Saad AM, Abushouk AI, et al. Procedural and short-term outcomes of percutaneous left atrial appendage closure in patients with cancer. Am J Cardiol 2021;141:154. DOI: https://doi.org/10.1016/j.amjcard.2020.12.003
24. Zweiker D, Bergler-Klein J, Fiedler L, et al. Left atrial appendage closure in atrial fibrillation patients with cancer. J Clin Med 2024;13:6514. DOI: https://doi.org/10.3390/jcm13216514
25. Galea R, Bini T, Krsnik JP, et al. Pericardial effusion after left atrial appendage closure: timing, predictors, and clinical impact. JACC Cardiovasc Interv 2024;17:1295-307. DOI: https://doi.org/10.1016/j.jcin.2024.01.310
26. Zou T, Chen Q, Zhang L, et al. Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion. Ann Transl Med 2021;9:1324. DOI: https://doi.org/10.21037/atm-21-3561
27. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. Heart 2020;106:569-74. DOI: https://doi.org/10.1136/heartjnl-2019-315852
How to Cite
1.
Ahmed M, Muskan F, Zaheer M, Kumar M, Gul S, Hadi Ansari A, et al. Safety and efficacy of left atrial appendage closure in cancer versus non-cancer patients: a systematic review and meta-analysis. Global Cardiol [Internet]. 2025 Jun. 16 [cited 2025 Jun. 17];. Available from: https://www.globalcardiology.info/site/article/view/72
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
